Can-Fite BioPharma Ltd. (CANF) stock

CANFNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026Score 1/30

$1.49−0.06 (-3.87%)

Close on Nov 12, 2026Market cap $1.95MP/E –Yield –

Can-Fite BioPharma gross margin

Gross margin is gross profit as a percentage of revenue.

Can-Fite BioPharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Can-Fite BioPharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3000 reverse split on Mar 26, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing